MGMT and glioblastoma: Nevertheless, baseline NLR was still prognostically independent of MGMT promoter methylation status (58, 129), IDH mutation status (51, 92, 121), and steroid use (122, 124) in patients with glioblastoma, and patients with increased NLR and requiring steroids had the poorest outcomes (73).